Compare Abeona Therapeutics Inc (ABEO) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: Abeona Therapeutics Inc is far larger — about 27.5× Avalanche Treasury Corporation Class A Common Stock's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ABEO | AVAT | |
|---|---|---|
Market Cap | $421.19M | $15.33M |
Sector | Health | Financials |
52-Week High | $7.45 | $10.75 |
52-Week Low | $4.17 | $0.30 |
Enterprise Value | $276.10M | $15.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
AVAT trades at $0.342, up 1.57% on the day, with a bearish technical signal from moving averages. The company reported a net income of $8.28 million for the current period but negative operating cash flow of -$930,710, indicating potential cash burn. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed; a low P/B of 0.4 suggests potential undervaluation, but negative cash flow and a bearish technical trend pose risks. Investment opportunity hinges on the company's ability to improve operational efficiency post-listing, while risks include sustained cash burn and competitive pressures in treasury management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
